Philippe Wiesel
Philippe is a biotech entrepreneur and clinical consultant specialized in product pipeline management and early stage clinical development. Previously, Philippe founded Genexion, a clinical development company focused on the assessment, elaboration and execution of early stage clinical development strategies for emerging biotech companies and European venture capital firms. Prior to Genexion, Philippe was a medical director at Serono's Swiss and US offices, where he was involved with the global development of several biologics and small molecules. In particular, he led the late stage clinical development of Raptiva to achieve the first marketing authorization in Europe for a biologic therapy targeting psoriasis.
Philippe also led the development of onercept in psoriasis and managed clinical development programs for beta interferon, interleukin-18 binding protein, TACI-Ig, and caspase inhibitors in several acute and chronic inflammatory diseases. Prior to joining the biotech industry, Philippe conducted basic research for over five years, studying signaling pathways leading to inflammatory gene responses in the laboratory of Professor Edgar Haber at the Harvard Medical School, and vascular biology at the Division of Hypertension led by Professor Hans Brunner in Lausanne, Switzerland. Philippe obtained his medical doctor degree from the University of Lausanne Medical School in 1993.